These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36722329)

  • 1. CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency Virus Cohort Study.
    Sangaré MN; Baril JG; de Pokomandy A; Klein M; Thomas R; Tremblay C; Pexos C; Durand M; Chawla S; Laporte L; Trottier H
    Clin Infect Dis; 2023 Jun; 76(11):1879-1888. PubMed ID: 36722329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
    Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
    Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
    Masiá M; Padilla S; Barber X; Sanchis M; Terol G; Lidón F; Gutiérrez F
    Medicine (Baltimore); 2016 Mar; 95(11):e3108. PubMed ID: 26986155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
    Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
    Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?
    Milanés-Guisado Y; Gutiérrez-Valencia A; Muñoz-Pichardo JM; Rivero A; Trujillo-Rodriguez M; Ruiz-Mateos E; Espinosa N; Roca-Oporto C; Viciana P; López-Cortés LF
    J Antimicrob Chemother; 2020 Jan; 75(1):200-207. PubMed ID: 31617904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
    Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
    J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART Strategies.
    Vos WAJW; Vadaq N; Matzaraki V; Otten T; Groenendijk AL; Blaauw MJT; van Eekeren LE; Brinkman K; de Mast Q; Riksen NP; Stalenhoef AFH; van Lunzen J; van der Ven AJAM; Blok WL; Stalenhoef JE
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort.
    Herrera S; Fernandez-Felix BM; Hunt PW; Deeks SG; Sainz T; Heath SL; Achenbach CJ; Rodríguez B; Mathews C; Christopoulos K; Mayer K; Napravnik S; Moreno S; Serrano-Villar S
    J Antimicrob Chemother; 2020 Jun; 75(6):1604-1610. PubMed ID: 32211777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens.
    Gianotti N; Muccini C; Galli L; Poli A; Spagnuolo V; Andolina A; Galizzi N; Ripa M; Messina E; Piatti PM; Lazzarin A; Castagna A
    J Med Virol; 2019 Nov; 91(11):1937-1943. PubMed ID: 31286527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
    Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
    J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.
    Han WM; Avihingsanon A; Rajasuriar R; Tanuma J; Mundhe S; Lee MP; Choi JY; Pujari S; Chan YJ; Somia A; Zhang F; Kumarasamy N; Tek Ng O; Gani Y; Chaiwarith R; Pham TN; Do CD; Ditangco R; Kiertiburanakul S; Khol V; Ross J; Jiamsakul A;
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):180-188. PubMed ID: 36625858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
    Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
    Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
    Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
    Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial antiretroviral therapy regimen and risk of heart failure.
    Silverberg MJ; Pimentel N; Leyden WA; Leong TK; Reynolds K; Ambrosy AP; Towner WJ; Hechter RC; Horberg M; Vupputuri S; Harrison TN; Lea AN; Sung SH; Go AS; Neugebauer R
    AIDS; 2024 Mar; 38(4):547-556. PubMed ID: 37967231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines.
    El Bouzidi K; Jose S; Phillips AN; Pozniak A; Ustianowski A; Gompels M; Winston A; Schaap A; Dunn DT; Sabin CA;
    AIDS; 2020 Oct; 34(12):1823-1831. PubMed ID: 32516283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
    Chen GJ; Cheng CY; Yang CJ; Lee NY; Tang HJ; Huang SH; Huang MH; Liou BH; Lee YC; Lin CY; Hung TC; Lin SP; Sun HY; Chang SY; Hung CC;
    J Antimicrob Chemother; 2024 May; 79(5):1157-1163. PubMed ID: 38546761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
    Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
    HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
    Pugliese P; Joly V; Valantin MA; Cotte L; Huleux T; Allavena C; Reynes J; Poizot-Martin I; Bani-Sadr F; Cuzin L;
    Med Mal Infect; 2019 Jun; 49(4):264-269. PubMed ID: 30409541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.